Ryan D Roberts
Overview
Explore the profile of Ryan D Roberts including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
1035
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dietz M, Al-Ibraheemi A, Davis J, Hawkins C, Craig B, Dasgupta R, et al.
J Natl Compr Canc Netw
. 2024 Dec;
23(1).
PMID: 39729709
Trends in diagnostic biopsy sample collection approaches for primary bone sarcomas have shifted in the past 2 decades. Although open/incisional biopsies used to be the predominant approach to obtain diagnostic...
2.
Khurshid S, Venkataramany A, Montes M, Kipp J, Roberts R, Wein N, et al.
Mol Ther Oncol
. 2024 Dec;
32(4):200908.
PMID: 39720325
Patients with osteosarcoma (OS), a debilitating pediatric bone malignancy, have limited treatment options to combat aggressive disease. OS thrives on insulin growth factor (IGF)-mediated signaling that can facilitate cell proliferation....
3.
Reinecke J, Jimenez Garcia L, Gross A, Cam M, Cannon M, Gust M, et al.
Clin Cancer Res
. 2024 Nov;
31(2):414-429.
PMID: 39540841
Purpose: Lung metastasis is responsible for nearly all deaths caused by osteosarcoma, the most common pediatric bone tumor. How malignant bone cells coerce the lung microenvironment to support metastatic growth...
4.
Moertel C, Hirbe A, Shuhaiber H, Bielamowicz K, Sidhu A, Viskochil D, et al.
J Clin Oncol
. 2024 Nov;
43(6):716-729.
PMID: 39514826
Purpose: Pharmacologic therapies for neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PNs) are limited; currently, none are US Food and Drug Administration-approved for adults. Methods: ReNeu is an open-label, multicenter, pivotal, phase...
5.
Lee U, Szabova L, Collins V, Gordon M, Johnson K, Householder D, et al.
Front Cell Dev Biol
. 2024 Nov;
12:1462840.
PMID: 39512899
Introduction: The topoisomerase 1 (TOP1) inhibitor irinotecan is a standard-of-care agent for relapsed Ewing sarcoma (EWS), but its efficacy is limited by chemical instability, rapid clearance and reversibility, and dose-limiting...
6.
Ringwalt E, Currier M, Glaspell A, Chen C, Cannon M, Cam M, et al.
Mol Ther Oncol
. 2024 Nov;
32(4):200886.
PMID: 39492947
We previously reported that the DNA alkylator and transcriptional-blocking chemotherapeutic agent trabectedin enhances oncolytic herpes simplex viroimmunotherapy in human sarcoma xenograft models, though the mechanism remained to be elucidated. Here...
7.
Upadhyay R, Klamer B, Matsui J, Chakravarthy V, Scharschmidt T, Yeager N, et al.
Cancers (Basel)
. 2024 Jun;
16(11).
PMID: 38893209
Background: Pediatric patients with metastatic and/or recurrent solid tumors have poor survival outcomes despite standard-of-care systemic therapy. Stereotactic ablative radiation therapy (SABR) may improve tumor control. We report the outcomes...
8.
Cripe T, Roberts R, Chandler D, Setty B, Chen S, Shenoy A, et al.
Mol Ther Oncol
. 2024 Apr;
32(1):200779.
PMID: 38596308
No abstract available.
9.
Ringwalt E, Currier M, Glaspell A, Chen C, Cannon M, Cam M, et al.
bioRxiv
. 2024 Mar;
PMID: 38464161
We previously reported that the DNA alkylator and transcriptional-blocking chemotherapeutic agent trabectedin enhances oncolytic herpes simplex viroimmunotherapy in human sarcoma xenograft models, though the mechanism remained to be elucidated. Here...
10.
Reinecke J, Jimenez Garcia L, Gross A, Cam M, Cannon M, Gust M, et al.
bioRxiv
. 2024 Jan;
PMID: 38260361
Purpose: Lung metastasis is responsible for nearly all deaths caused by osteosarcoma, the most common pediatric bone tumor. How malignant bone cells coerce the lung microenvironment to support metastatic growth...